ライフサイエンスコーパス: viral shedding

1 n healing, pain resolution, and cessation of viral shedding).

2 ntly declined among participants with no/low viral shedding.

3 DNAemia and limited tissue dissemination and viral shedding.

4 thus controlling both recurrent lesions and viral shedding.

5 n subjects with similar illness severity and viral shedding.

6 ce remain infected for life, with periods of viral shedding.

7 n the mid-1980s showed nearly constant fecal viral shedding.

8 because lesions are accompanied by frequent viral shedding.

9 viral titers and decreasing the duration of viral shedding.

10 duration (P = .001) and titer (P = .005) of viral shedding.

11 l reactivation by explantation or peripheral viral shedding.

12 a exist about oseltamivir's ability to alter viral shedding.

13 t seen in convalescent mice eliminated nasal viral shedding.

14 ant increase in the risk of complications or viral shedding.

15 loss of lesion pain and time to cessation of viral shedding.

16 10 animals fed intravenous TPN had continued viral shedding.

17 ques and may be useful in evaluation genital viral shedding.

18 integral features of CMV pneumonitis but not viral shedding.

19 gating asymptomatic patients, and monitoring viral shedding.

20 monitored for clinical signs of disease and viral shedding.

21 isease course, patient-specific factors, and viral shedding.

22 illness, and with lower Ct values and longer viral shedding.

23 mal signs of disease, with only intermittent viral shedding.

24 ve days reduces its efficacy in curbing peak viral shedding.

25 ing as a reservoir for recurrent disease and viral shedding.

26 follicles, suggesting a novel mechanism for viral shedding.

27 of VVC, and VVC is associated with increased viral shedding.

28 ective against symptomatic RSV infection and viral shedding.

29 resulting in pathological recurrence and/or viral shedding.

30 onsistent with the peak level of viremia and viral shedding.

31 s complicated by recrudescence of high-grade viral shedding.

32 iratory disease and/or prolonged duration of viral shedding.

33 opment of antibody did not have an impact on viral shedding.

34 5 sequential mid-turbinate swabs to measure viral shedding.

35 lted in different degrees of lung damage and viral shedding.

36 sulted in different degrees of pathology and viral shedding.

37 ection causes recurrent lesions and frequent viral shedding.

38 and lower respiratory tract and much reduced viral shedding.

39 ved survival and reduced genital lesions and viral shedding.

40 ot serum antibodies, correlated with reduced viral shedding.

41 vival but did not reduce genital lesions and viral shedding.

42 th the throat viral load and the duration of viral shedding.

43 g resistance, most probably due to prolonged viral shedding.

44 ntly declined among participants with no/low viral shedding (-0.04 +/- 0.02, P = 0.047, interaction P

45 ive for adenovirus (incidence 23.5%), 23 for viral shedding, 23 for infections.

46 , 15 episodes (17%) had instances of seminal viral shedding 400 copies/mL despite viral suppression i

47 train EDIM) induced complete protection from viral shedding after challenge for at least 6 weeks afte

48 partial protection, characterized by reduced viral shedding after challenge.

49 vaccines were well tolerated, and prolonged viral shedding after LAIV was not detected.

50 zing capacity, associated with no detectable viral shedding after repeat challenge infection.

51 indication of ISS efficacy, the magnitude of viral shedding also was significantly reduced in ISS-tre

52 al exposure to BKPyV due to the high rate of viral shedding among hematology patients.

53 ys (43.0%; 95% CI, 39.8%-46.5%) with genital viral shedding among persons with symptomatic genital HS

54 through 59 months in the immunogenicity and viral shedding analyses.

55 Of 37 participants challenged, 16 (43%) had viral shedding and 27 (73%) developed symptoms, with 12

56 Immunosuppression leads to greater viral shedding and altered severe acute respiratory synd

57 Viral shedding and clinical disease were evaluated daily

58 ses have similar characteristics in terms of viral shedding and clinical illness.

59 , and HA stalk antibody levels and influenza viral shedding and disease duration using accelerated fa

60 tients face a considerable risk of prolonged viral shedding and emergence of escape mutations after e

61 Days of viral shedding and IL-6 but not IL-8 concentrations were

62 es protective immunity that can reduce acute viral shedding and latent infection in a mouse genital m

63 e cohort of 128 HSV-2-infected persons whose viral shedding and lesion frequency was measured by dail

64 -existing immunity show reduced alpha-swH1N2 viral shedding and less severe disease signs.

65 induced diarrhea; however, there was reduced viral shedding and mortality in the icPEDV-EnUmt-infecte

66 Viral shedding and nasal IgA levels were measured in add

67 otracted infection was defined as persistent viral shedding and prolonged symptoms unresponsive to an

68 Since most cases of human viral shedding and reactivation are not associated with

69 eneral, host immunity is sufficient to clear viral shedding and recurrences, although it is insuffici

70 avn virus-infected bats had higher levels of viral shedding and shed the virus for a longer period, p

71 gression to severe COVID-19, or cessation of viral shedding and should not be used to treat patients

72 The viral shedding and susceptibility to infection we observ

73 ay 3 in plasma, day 4 in nasal fluids), when viral shedding and symptoms were subsiding.

74 fferences can result in the disparity of the viral shedding and tissue tropism.

75 mucosal immune reaction would help to reduce viral shedding and transmission locally.

76 virus (HSV) infection, but they cannot stop viral shedding and transmission.

77 easures were frequency of infection based on viral shedding and/or seroconversion (prophylaxis) or qu

78 a scenario with R0 = 3.0, 60% presymptomatic viral shedding, and a dialysis patient being the infecti

79 were associated with significantly shortened viral shedding, and among adults they were also associat

80 n continued protection against infection, no viral shedding, and boosting of the immune response.

81 ral entry, and thereby protect from disease, viral shedding, and cell-associated viremia.

82 Subjects were followed up for clinical take, viral shedding, and immune responses.

83 with lower [corrected] symptom scores, less viral shedding, and improved health, activity, and sleep

84 e incidence of reactivation and asymptomatic viral shedding, and limit morbidity and mortality from a

85 and N-antigen, burden of RNA and infectious viral shedding, and lower Spike-specific IgG levels with

86 ad more severe disease/complications, longer viral shedding, and more antiviral resistance while demo

87 d mild to moderate diarrhea, lower titers of viral shedding, and no mortality, whereas the icPC22A vi

88 esponses in MDA-positive pigs, reduced nasal viral shedding, and prevented lung lesions.

89 Subjects were monitored for symptoms, viral shedding, and safety, including cytokine measureme

90 d by survival, weight loss, activity scores, viral shedding, and seroconversion.

91 mab decreased the duration of RV infections, viral shedding, and the risk of RV illnesses.

92 CD8(+) T cells in ss7(-/-) animals prolonged viral shedding, and transfer of immune ss7(-/-) CD8(+) T

93 time after infection, but data on long-term viral shedding are lacking.

94 outcomes, seroconversion, and persistence of viral shedding are unexplored.

95 n high association between the CPV score and viral shedding, as long as the timing of these sessions

96 Prolonged viral shedding, as observed in immunocompromised individ

97 ril in decreasing the signs and symptoms and viral shedding associated with a viral respiratory infec

98 mock-treated HEV-infected pigs cleared fecal viral shedding at 8 wk postinfection.

99 n treatment showed a significant decrease in viral shedding at day 3 relative to monotherapy, this di

100 The transmission of herpesviruses depends on viral shedding at mucosal surfaces.

101 ; however, vaccinated animals showed reduced viral shedding at multiple time points after infection.

102 though CXCL1 knockout mice display increased viral shedding at the cornea.

103 seroconversion (prophylaxis) or quantitative viral shedding based on titers and duration of virus rec

104 Greater reductions in viral shedding, based on median tissue culture infective

105 allowing for detection of a 50% reduction in viral shedding between the study treatments.

106 We compared the patterns of influenza viral shedding between these groups.

107 icantly reduced IAV titers and shortened the viral shedding but did not completely block direct conta

108 in household contacts by 35% (p = 0.006) and viral shedding by >=0.5 log(10)/day (p = 0.04).

109 buffer, compared with normal saline, reduced viral shedding by 1 log unit (10(3) vs. 10(4) 50% tissue

110 titers by 2.0 log10, the median duration of viral shedding by 3 days, and the frequency of febrile i

111 ter 7 times normal was needed to lower nasal viral shedding by 98%.

112 y, this data was used to demonstrate chronic viral shedding by an immunocompromised, hospital-acquire

113 on of oseltamivir treatment with duration of viral shedding by polymerase chain reaction or with the

114 Recent studies suggest that viral shedding can vary strikingly among infected cells.

115 Viral shedding ceased in 13 (87%) of 15 cidofovir-treate

116 the single AA331 or AA385 mutant had reduced viral shedding, comparable to cell-culture passaged CDC-

117 ract disease (LRD), hypoxemia, and prolonged viral shedding compared with seasonal influenza A.

118 refed enterally for 5 days were positive for viral shedding, compared with 8 of 12 matched TPN-fed an

119 RNA throughout lactation and more-consistent viral shedding, compared with mothers who did not transm

120 ht reflect differences in incubation period, viral shedding, contact, or susceptibility.

121 Frequent viral shedding contributed to a high rate of infection,

122 The duration of viral shedding correlated with the magnitude of the NAb

123 ross all studies, suggesting an adherence of viral shedding counts to the Pareto Principle.

124 o analyze jointly both symptom reporting and viral shedding data from a three-armed study of influenz

125 roconversion was high and the persistence of viral shedding deserves further studies.

126 ion from respiratory samples, variability in viral shedding duration, lack of effective therapy, and

127 ell as in the accurate determination of live viral shedding during convalescence to inform decisions

128 The nature of influenza viral shedding during naturally acquired infection is no

129 Individual variations in viral shedding dynamics may lead to either premature end

130 yngeal and saliva samples displayed distinct viral shedding dynamics, and salivary viral burden corre

131 CE Sexual transmission of HSV-2 results from viral shedding following reactivation from latency.

132 y correlated with protection from developing viral shedding following virus challenge at day 90 and c

133 Forty-two participants (43%) had viral shedding for 1 day (median peak viral load cycle t

134 enza disease in 69% of individuals with mean viral shedding for 4-5 days and significant rises in con

135 ients with 2009 H1N1 influenza pneumonia had viral shedding for over 5 weeks despite therapy with ose

136 collected air and surface samples to examine viral shedding from isolated individuals.

137 olling and will evaluate the effect of 4b on viral shedding from sanctuary sites in EBOV survivors.

138 or did such therapy decrease the duration of viral shedding from the nasopharynx among patients with

139 respiratory tract infection in 12 (67%), and viral shedding from the nasopharynx was prolonged for 7

140 d killed 40 hours postchallenge to determine viral shedding from the upper respiratory tract.

141 al virus and killed at 40 hours to determine viral shedding from the upper respiratory tract.

142 synergy in vitro and in vivo, and restricted viral shedding from the upper respiratory tract.

143 , 15 episodes (17%) had instances of seminal viral shedding >=400 copies/mL despite viral suppression

144 Prolonged viral shedding has been reported in semen, suggesting th

145 rventions if RT-PCR detection occurred after viral shedding has likely ceased.

146 The relationships between host factors, viral shedding, illness severity, and antibody response

147 luenza vaccine (LAIV) for immunogenicity and viral shedding in a randomized, placebo-controlled trial

148 of the prevalence, duration, and quantity of viral shedding in all participants.

149 There was no viral shedding in any animal fed via the gastrointestina

150 contrast, there was no difference in ocular viral shedding in B6-E mice transplanted with 129 or B6

151 reshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool.

152 systemic infection and frequent, high-titer viral shedding in bodily fluids occurred following oral

153 Safety evaluations included adverse events, viral shedding in body fluids, and vector antibody respo

154 of the placenta and genital tract; increased viral shedding in breast milk from inflammation of breas

155 therapy and emergence of drug resistance on viral shedding in children infected with influenza A or

156 therapy, and emergence of drug resistance on viral shedding in children infected with influenza A or

157 s led to reduced viral loads in the lung and viral shedding in faeces, and also alleviated the inflam

158 can establish chronic infections with active viral shedding in healthy humans but whether persistence

159 therapies may lead to prolonged disease and viral shedding in individuals infected with severe acute

160 The frequency of viral shedding in men with genital herpes appears compar

161 t of fever, lesion appearance, peak viremia, viral shedding in nasal and oral swabs, peak cytokine le

162 aled statistically significant reductions in viral shedding in nasal secretions (P<.001), nasal mucus

163 No clinical signs of FMD, viremia, or viral shedding in nasal swabs was found in the Ad5-boIFN

164 athology and viral load in the lungs but not viral shedding in nasal swabs.

165 Time to clinical resolution and change in viral shedding in nasopharyngeal specimens were the prim

166 ategies to reduce PV replication to diminish viral shedding in OPV recipients.

167 points were duration of clinical illness and viral shedding in patients treated less than and more th

168 The presence of influenza viral shedding in patients with influenza who have very

169 The timing and intensity of respiratory viral shedding in patients with MERS closely matches tha

170 or oseltamivir to reduce patient illness and viral shedding in people with influenza, in whom treatme

171 s but that only a few of these may result in viral shedding in pigs upon infection, providing opportu

172 affects young children and causes prolonged viral shedding in saliva and urine.

173 me polymerase chain reaction in blood and by viral shedding in saliva, in 878 people aged 3 to 89 yea

174 DNA detection by real-time PCR, in blood and viral shedding in saliva, in 878 people aged 3 to 89 yea

175 n, while the transmission of KSHV occurs via viral shedding in saliva.

176 ation, while transmission of KSHV occurs via viral shedding in saliva.

177 infection in MSM enrolled on PrEP and assess viral shedding in seropositive participants.

178 er biopsies concurrent with the detection of viral shedding in stool, and NV antigen expression was o

179 irradiation, vaccinated mice showed reduced viral shedding in tears as well as a reduction in the in

180 erity of genital lesions and lower levels of viral shedding in the genital tract after HSV-2 challeng

181 Seropositivity for HSV-2 is associated with viral shedding in the genital tract, even in subjects wi

182 ecreased change from baseline viral load and viral shedding in the multiple-dose group compared with

183 eral nutrition-fed animals continued to have viral shedding in the nasal passages compared to one of

184 Treatment with 0.5 mg/kg HNK20 reduced viral shedding in the nose, throat, and lungs by 3-4 log

185 ivor group (p=0.02) and in the subgroup with viral shedding in the semen (p=0.02).

186 Viral shedding in the semen can increase the risk of ZIK

187 In survivors with viral shedding in the semen compared with controls, VEGF

188 intestinal tissue viral titers and increased viral shedding in the stool.

189 o adrenergically induced reactivation, i.e., viral shedding in the tears, compared with rabbits infec

190 reports have describe high-level persistent viral shedding in the urine of infected patients, but th

191 ents, the proportion of participants showing viral shedding in their stools, the time to cessation of

192 Oseltamivir decreased viral shedding in this low-risk population.

193 Most importantly, NTZ reduces viral shedding in vivo, exhibiting its potential as a fu

194 nificant decreases in a composite serotype 2 viral shedding index after mOPV2 challenge.

195 on as measured by both recurrent disease and viral shedding into the genital tract.

196 oung children who acquire CMV have prolonged viral shedding into the urine and saliva, but whether th

197 Duration of viral shedding is a determinant of infectivity and trans

198 Viral shedding is associated with a transient drop in th

199 Viral shedding is highest before symptom onset, suggesti

200 e first 3 days of parotitis, suggesting that viral shedding is minimal after the first 3 days of symp

201 the infection risk caused by 1 virus copy in viral shedding is on the order of 10-6 to 10-5.

202 are common in the first 100 days after HCT, viral shedding lasts more than 3 weeks in half, and lowe

203 Bs demonstrated marked heterogeneity in RAVV viral shedding loads consistent with the Pareto Principl

204 ad significantly higher and prolonged rectal viral shedding loads, as well as significantly prolonged

205 ly prevents severe illness but also curtails viral shedding, lowering transmission risks from treated

206 h persistently infected (PI) cells extending viral shedding, maintaining inflammation, and providing

207 The rate of viral shedding measured by quantitative real-time fluore

208 al and fecal samples were self-collected for viral shedding measured by reverse-transcriptase-polymer

209 Viral shedding measured from nasal and throat swabs, bro

210 Evaluation of viral shedding, nasal and serum cytokines, clinical illn

211 neither shortened the duration of SARS-CoV-2 viral shedding nor improved symptoms in outpatients with

212 mptom severity peaked on day 3, whereas most viral shedding occurred 1-2 days after challenge.

213 ease (3 to 4 logs) in ocular, but not nasal, viral shedding occurred during acute infection relative

214 No viral shedding occurred in the group immunised with BHPI

215 Peak viral shedding occurred on days 7-9 after infection.

216 role of variant and host in individual-level viral shedding of VOCs is essential to inform Coronaviru

217 They experienced 238 episodes of viral shedding, of which 23 (10%) were not accompanied b

218 tract (FGT) are critical for suppression of viral shedding or effective preexposure prophylaxis.

219 responses and offered no protection against viral shedding or lung damage.

220 therapy appears to be inadequate in reducing viral shedding or mortality once pneumonia is establishe

221 linic to demonstrate sustained depression of viral shedding or protection from recurrences.

222 atients were alive without clinical signs of viral shedding or recurrent or active infection.

223 Acebilustat did not affect viral shedding or symptoms at day 120.

224 s in living quarters and extended pharyngeal viral shedding over the course of several days.

225 g typical COVID-19 symptoms, suggesting high viral shedding (P = .007).

226 comparing model accuracies across different viral shedding patterns and by parameterizing our model

227 zation could affect transmission by altering viral shedding patterns.

228 tal treatment did not influence asymptomatic viral shedding patterns.

229 Fecal viral shedding persisting for 8 days was detected by bot

230 However, viral shedding persists at high rates and copy numbers y

231 .6%]; P = 0.93), had significantly decreased viral shedding (positive cultures compared with total cu

232 ee serotypes and intestinal immunity (faecal viral shedding post-challenge) to serotype 2, analysed i

233 pQAC-N showed reduced clinical severity and viral shedding postchallenge on par with protection obse

234 Viral shedding preceded symptoms by 12-24 hours and term

235 moderate disease characterized by consistent viral shedding, pulmonary infiltrates, and elevated infl

236 two tests was highest early in the course of viral shedding (r = 0.91, days 0 to 6), whereas during d

237 Our analysis suggests that the duration of viral shedding ranges from 23 to 50 days between individ

238 The overall viral shedding rate among men (n = 247) with evidence of

239 The total viral shedding rate in HSV-2-seropositive men was 5%; th

240 In the prophylaxis trial, the viral shedding rate satisfied the Prentice definition fo

241 Viral shedding rates were correlated for those with the

242 mmune responses to OPV but not the prolonged viral shedding required to form iVDPV.

243 promised patients often experience prolonged viral shedding, resulting in an increased risk of viral

244 opulation for the primary analysis had day 3 viral shedding results.

245 Viral shedding, secretion weights, symptom scores, and c

246 Importantly, viral shedding significantly increased in pDC-deficient

247 ess common in children than adults, although viral shedding still occurs in asymptomatic children.

248 e type I IFN receptor had minimal effects on viral shedding, suggesting that endogenous type I IFN si

249 sponses were noted during the peak period of viral shedding, suggesting that protection was due to sp

250 tion of a high Treg to Tconv ratio with high viral shedding suggests that the balance between regulat

251 with placebo, rimantadine treatment reduced viral shedding, systemic symptoms, and levels of IL-8.

252 racted SARS-CoV-2 infections with persistent viral shedding that could pose a wider public health ris

253 simplex virus 2 (HSV-2) from latency causes viral shedding that develops into recurrent genital lesi

254 n, with a prolonged period of oral and nasal viral shedding that is not accompanied by clinical signs

255 nfluenza infection, aged mice have prolonged viral shedding that is presumably due to lower anti-infl

256 ng in their stools, the time to cessation of viral shedding, the cell culture infective dose of shed

257 ngitudinal daily symptom scores, duration of viral shedding through day 10, and symptoms on day 120.

258 Reduced viral shedding titers were correlated with significantly

259 /77 as defined by substantial differences in viral shedding trajectories.

260 l performance largely depends on a monotonic viral shedding trajectory following case detection.

261 ssociated with strain-specific prevention of viral shedding upon LAIV receipt.

262 Molecular viral shedding values follow symptom scores, but timing

263 Median duration of viral shedding was 3 weeks; prolonged shedding of at lea

264 ing placebo, the median time to cessation of viral shedding was 7 days (hazard ratio [HR] = 0.81; 95%

265 e was analyzed by in situ hybridization, and viral shedding was assessed by quantitative PCR.

266 measured at days 0, 7, 28, and 56, and stool viral shedding was assessed up to 28 days post-vaccinati

267 Viral shedding was associated with increases in local an

268 In one case, viral shedding was cleared without evidence of maribavir

269 Importantly, the frequency of recurrent viral shedding was considerably reduced in GEN-003/MM-2-

270 eatinine clearances were lower at times when viral shedding was detected (P=0.038).

271 Ten LAIV recipients shed virus; the latest viral shedding was detected 7 days after vaccination.

272 Viral shedding was detected in only six (6%) of 101 part

273 Viral shedding was measured at 42 hours after challenge.

274 Viral shedding was monitored by tear film cultures.

275 Vaccine viral shedding was not detected in any subject, confirmi

276 Viral shedding was not influenced by primary diagnosis,

277 Prolonged viral shedding was not noted, and the patients recovered

278 he patients improved promptly, and prolonged viral shedding was not noted.

279 Persistence of viral shedding was observed in 21% of the patients witho

280 Prolonged viral shedding was observed in a minority of patients.

281 In one child, viral shedding was observed in two stools obtained 91 da

282 ported in the literature, but information on viral shedding was only available for 40 case-patients.

283 Surprisingly, H1N1pdm viral shedding was reduced in animals vaccinated with MV

284 The duration of viral shedding was reduced, however, among children who

285 ly lower, and the duration of nasopharyngeal viral shedding was shorter in some vaccinated monkeys af

286 Even when viral shedding was significantly reduced following chall

287 imens from HSV-2 positive women, genital HIV viral shedding was similar during symptomatic and asympt

288 ents, greater peak CMV DNAemia and increased viral shedding were associated with stronger CD8+ respon

289 Predictors of viral shedding were determined using backwards selection

290 nd systemic adverse events (AEs) and vaccine viral shedding were monitored.

291 Mean days of cutaneous viral shedding were reduced from 3.3 in the placebo grou

292 Both duration and peak titer of viral shedding were reduced in MVA recipients.

293 Acceptability, symptom duration and viral shedding were secondary outcomes.

294 Last, participants with a single day of viral shedding were three times more likely to be female

295 s, such as recurrent parotitis and prolonged viral shedding, were observed mostly in Marshallese indi

296 e of immunosuppression, leading to increased viral shedding, which could interfere with long term mis

297 Six participants (6%) had 1 to 6 days of viral shedding with censored duration.

298 The relative risk of viral shedding with pritelivir, as compared with placebo

299 p (n = 13), and the median (IQR) duration of viral shedding with therapy was reduced from 107 (83-131

300 al herpes, and we compared their patterns of viral shedding with those in a similar cohort of 90 subj